These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 36642717

  • 1. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study.
    Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, Asano K, Endo A, Uezono S.
    BMC Nephrol; 2023 Jan 16; 24(1):12. PubMed ID: 36642717
    [Abstract] [Full Text] [Related]

  • 2. Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study.
    Kameda S, Maeda A, Maeda S, Inoue Y, Takahashi K, Kageyama A, Doi K, Fujii T.
    BMC Nephrol; 2024 Feb 26; 25(1):69. PubMed ID: 38408970
    [Abstract] [Full Text] [Related]

  • 3. Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
    Miyaji MJ, Ide K, Takashima K, Maeno M, Krallman KA, Lazear D, Goldstein SL.
    Pediatr Nephrol; 2022 Nov 26; 37(11):2733-2742. PubMed ID: 35348901
    [Abstract] [Full Text] [Related]

  • 4. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study.
    Liu D, Zhao J, Xia H, Dong S, Yan S, Zhuang Y, Chen Y, Peng H.
    Eur J Med Res; 2024 Jan 20; 29(1):72. PubMed ID: 38245802
    [Abstract] [Full Text] [Related]

  • 5. Association of anticoagulation use during continuous kidney replacement therapy and 90-day outcomes: A multicentre study.
    Lau YH, Li AY, Lim SL, Woo KL, Ramanathan K, Chua HR, Akalya K, Tan AY, Phua J, Tan JJ, Puah SH, Chia YW, Loh SC, Ahmed Khan F, Chatterjee S, Kaushik M, See KC, Society of Intensive Care Medicine (Singapore)-National Investigators for Epidemiology and Research (SICM-NICER).
    Ann Acad Med Singap; 2023 Aug 30; 52(8):390-397. PubMed ID: 38920170
    [Abstract] [Full Text] [Related]

  • 6. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
    Zarbock A, Küllmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, Dimski T, Tyczynski B, Jahn M, Mülling N, Mehrländer M, Rosenberger P, Marx G, Simon TP, Jaschinski U, Deetjen P, Putensen C, Schewe JC, Kluge S, Jarczak D, Slowinski T, Bodenstein M, Meybohm P, Wirtz S, Moerer O, Kortgen A, Simon P, Bagshaw SM, Kellum JA, Meersch M, RICH Investigators and the Sepnet Trial Group.
    JAMA; 2020 Oct 27; 324(16):1629-1639. PubMed ID: 33095849
    [Abstract] [Full Text] [Related]

  • 7. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY.
    Int J Artif Organs; 2013 Mar 27; 36(3):208-16. PubMed ID: 23404639
    [Abstract] [Full Text] [Related]

  • 8. Filter Lifespan, Treatment Effect, and Influencing Factors of Continuous Renal Replacement Therapy for Severe Burn Patients.
    Yue Q, Wu H, Xi M, Li F, Li T, Li Y.
    J Burn Care Res; 2024 May 06; 45(3):764-770. PubMed ID: 38113522
    [Abstract] [Full Text] [Related]

  • 9. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
    Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S.
    Int J Artif Organs; 2016 Jan 06; 39(1):16-21. PubMed ID: 26868216
    [Abstract] [Full Text] [Related]

  • 10. Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study.
    Valle EO, Cabrera CPS, Albuquerque CCC, Silva GVD, Oliveira MFA, Sales GTM, Smolentzov I, Reichert BV, Andrade L, Seabra VF, Lins PRG, Rodrigues CE.
    Crit Care; 2021 Aug 19; 25(1):299. PubMed ID: 34412667
    [Abstract] [Full Text] [Related]

  • 11. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study.
    Rhee H, Berenger B, Mehta RL, Macedo E.
    Am J Kidney Dis; 2021 Oct 19; 78(4):550-559.e1. PubMed ID: 33798636
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
    Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y.
    Cochrane Database Syst Rev; 2020 Mar 13; 3(3):CD012467. PubMed ID: 32164041
    [Abstract] [Full Text] [Related]

  • 13. Dialysis circuit clotting in critically ill patients with COVID-19 infection.
    Khoo BZE, Lim RS, See YP, Yeo SC.
    BMC Nephrol; 2021 Apr 20; 22(1):141. PubMed ID: 33879086
    [Abstract] [Full Text] [Related]

  • 14. Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Lins PRG, de Albuquerque CCC, Assis CF, Rodrigues BCD, E Siqueira Campos BP, de Oliveira Valle E, Cabrera CPS, de Oliveira Gois J, Segura GC, Strufaldi FL, Mainardes LC, Ribeiro RG, Via Reque Cortes DDP, Lutf LG, de Oliveira MFA, Sales GTM, Smolentzov I, Reichert BV, Andrade L, Seabra VF, Rodrigues CE.
    Trials; 2020 Nov 11; 21(1):920. PubMed ID: 33176886
    [Abstract] [Full Text] [Related]

  • 15. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial.
    Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, Vervloet MG, Beishuizen A, Girbes AR, Ter Wee PM, Groeneveld AB, CASH study group.
    Crit Care; 2014 Aug 16; 18(4):472. PubMed ID: 25128022
    [Abstract] [Full Text] [Related]

  • 16. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill children.
    Sık G, Demirbuga A, Annayev A, Citak A.
    Int J Artif Organs; 2020 Apr 16; 43(4):234-241. PubMed ID: 31856634
    [Abstract] [Full Text] [Related]

  • 17. How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes.
    Qian Y, Wu W, Wang M, Wei Y, Zhong M.
    BMC Nephrol; 2024 Sep 20; 25(1):314. PubMed ID: 39304801
    [Abstract] [Full Text] [Related]

  • 18. Regional citrate anticoagulation for continuous renal replacement therapy in children.
    Rico MP, Fernández Sarmiento J, Rojas Velasquez AM, González Chaparro LS, Gastelbondo Amaya R, Mulett Hoyos H, Tibaduiza D, Quintero Gómez AM.
    Pediatr Nephrol; 2017 Apr 20; 32(4):703-711. PubMed ID: 27896442
    [Abstract] [Full Text] [Related]

  • 19. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
    Lee YK, Lee HW, Choi KH, Kim BS.
    PLoS One; 2014 Apr 20; 9(10):e108737. PubMed ID: 25302581
    [Abstract] [Full Text] [Related]

  • 20. Citrate versus unfractionated heparin for anticoagulation in continuous renal replacement therapy.
    Liao YJ, Zhang L, Zeng XX, Fu P.
    Chin Med J (Engl); 2013 Apr 20; 126(7):1344-9. PubMed ID: 23557569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.